Myeloproliferative Neoplasms | Topics

 
Abdulraheem Yacoub, MD, on Advancing Outcomes for Patients With Myelofibrosis and Myeloproliferative Neoplasms
April 21, 2021

CancerNetwork® spoke with Abdulraheem Yacoub, MD, during the American Association for Cancer Research Annual Meeting 2021 to discuss how predictors of response to therapy may be just as important as the development of new therapies for advancing outcomes in myelofibrosis and myeloproliferative neoplasms.

Parsaclisib Plus Ruxolitinib to Treat Myelofibrosis Improves Spleen Size and Symptom Burden
April 11, 2021

Adding parsaclisib to the ruxolitinib treatment of patients with myelofibrosis who had a suboptimal response on a standard dose of ruxolitinib alone led to improvements in spleen volume reduction and symptom burden.

High-Dose Imetelstat Improves OS, Offers Clinical Benefit in High-Risk Myelofibrosis
December 05, 2020

The telomerase inhibitor demonstrated improved overall survival spleen response, and symptom response in patients with myelofibrosis.